FDA Requires Label Update for Agios Pharmaceuticals' Pyrukynd

Among significant news last week, the US Food and Drug Administration (FDA) required Agios Pharmaceuticals to amend the label for its hemolytic anemia drug Pyrukynd to reflect the risk of liver injury. Swiss ophthalmic drugs developer Oculis Holdings released positive Phase II results for its OCS-05. US drug developer Climb Bio entered into a licensing deal with China-based Mabworks Biotech on the latter’s monoclonal antibody CLYM116/MIL116. Also of note, US CRISPR gene editing company Intellia Therapeutics announced strategic plans which included cuts in programs and workforce.